Completed PHASE2 INTERVENTIONAL 5-arm NCT00102687

Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes

A Multicenter, Randomized, Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes

Sponsor: Celgene

Conditions Myelodysplastic Syndromes

Interventions azacitidine

Updated 8 times since 2017 Last updated: Nov 7, 2019 Started: Jan 1, 2005 Primary completion: Aug 1, 2008 Completion: Aug 1, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Myelodysplastic Syndromes and is currently completed. Celgene leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Dec 2019 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Dec 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene

Data source: Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Bakersfield, United States , Bedford, United States , Beverly Hills, United States , Burien, United States , Colorado Springs, United States , Dallas, United States , Denver, United States , Edmonds, United States , Fort Worth, United States and 21 more locations